ArticleTranslational cancer research2026

UV1 plus pembrolizumab in recurrent and metastatic head and neck squamous cell carcinoma: safe, immunogenic, but lacking efficacy.

Guillermo Flores et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.